One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

May 3, 2016

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017.  Additionally, an

Immunotherapy cells

News and Notes for the Carcinoid and Neuroendocrine Tumor Community, April 2016

April 25, 2016

Rare Neuroendocrine Skin Cancer Treated by Immunotherapy

Merkel cell carcinoma, a rare neuroendocrine virus-linked skin cancer, has been added to the list of cancers that can be treated by immunotherapy. Scientists who led the clinical study of the…

Diane Reidy Lagunes, MD, Memorial Sloan Kettering_2

News and Notes for the Carcinoid and Neuroendocrine Tumor Community, March 2016

March 23, 2016

Breaking News from Advanced Accelerator Applications (AAA) about PRRT Treatment— Advanced Accelerator Applications announced on March 23 that the company has initiated an expanded access program (EAP) in the United States for the investigational…

Jonathan Strosberg on NETTER-1

Neuroendocrine Tumors to Be Focus of Presentations and Posters at ASCO Gastrointestinal Cancers Symposium

January 14, 2016

Presentations on recent advances in the treatment of neuroendocrine tumors (NETs) and new findings from the NETTER-1 clinical study on PRRT with Lutathera along with posters on a wide variety of subjects about NETs will be part of the program during the…


10 Highlights of the Year 2015 for the Carcinoid and Neuroendocrine Tumor Community

January 5, 2016

As we begin a new year, the Carcinoid Cancer Foundation looks back on the highlights of 2015 and to a future that we hope will bring greater awareness of carcinoid and neuroendocrine cancers, earlier diagnosis for patients, new treatment options, and …

Jennifer Chan, MD and Matthew Kulke, MD

Neuroendocrine Tumors Focus of Upcoming Issue of Hematology/Oncology Clinics

November 27, 2015

Neuroendocrine Tumors will be featured in the February 2016 issue of Hematology/Oncology Clinics. Dr. Jennifer Chan and Dr. Matthew Kulke, both from Dana-Farber Cancer Institute in Boston, Massachusetts are Editors of the issue, published by Elsevier.…


10 Highlights for the Carcinoid and Neuroendocrine Tumor Community

June 12, 2015
  • PET/CT using Gallium-68 DOTATOC captures hidden source of neuroendocrine cancer. “An investigational molecular imaging technique could be the key to finding the elusive primary tumor, say presenters at the 2015 Annual Meeting of the Society
Clinical Trial Rider Insurance Policy from Golden Rule

DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment

June 8, 2015

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…

Carcinoid/neuroendocrine cancer specialist Eric Liu, MD Joins Rocky Mountain Cancer Centers

9 More News Items for the Carcinoid and Neuroendocrine Cancer Community

May 19, 2015

Carcinoid/neuroendocrine cancer specialist Dr. Eric Liu will be joining the Rocky Mountain Cancer Centers in Denver, Colorado, effective June 1, 2015. He and medical oncologist Dr. Allen Cohn, also from Rocky Mountain Cancer Centers, will head up …

3rd Theranostics World Congress

3rd Theranostics World Congress Offers Free Patient Program on March 14

February 27, 2015

Johns Hopkins University in Baltimore, Maryland will be the site of the 3rd Theranostics World Congress on Ga-68 & PRRT from March 12-14, 2015. Co-sponsored by the Society of Nuclear Medicine and Molecular Imaging and Johns Hopkins Medicine, the…